Condensed Consolidated Financial Statement Details (Tables)

6 Months Ended

Jun. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):

	June 30, 2024		December 31, 2023
Raw materials	$	1,719	$	1,861
Work-in-process		10,590		12,880
Finished goods		2,156		1,360
Total inventory, net	$	14,465	$	16,101

Schedule of Other Current Assets

Other current assets consist of the following (in thousands):

	June 30, 2024		December 31, 2023
Prepaid research and development expenses	$	4,214	$	4,325
Interest and other non-trade receivables		1,703		1,047
Other prepaid expenses		2,375		4,407
Total other current assets	$	8,292	$	9,779

Schedule of Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

	June 30, 2024			December 31, 2023
Building and leasehold improvements	$	41,867		$	43,184
Computer equipment and computer software		22,118			22,438
Manufacturing equipment		23,980			24,315
Laboratory equipment		14,385			14,537
Furniture, fixtures and other		541			541
Depreciable property, plant and equipment at cost		102,891			105,015
Less: accumulated depreciation		(88,428	)		(86,898	)
Depreciable property, plant and equipment, net		14,463			18,117
Construction in process		724			739
Property, plant and equipment, net	$	15,187		$	18,856

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

	June 30, 2024		December 31, 2023
Accrued compensation	$	8,715	$	5,553
Accrued research and development expenses		11,060		10,118
Accrued contract termination costs		3,357		3,020
Other accrued expenses		6,382		3,471
Total accrued expenses	$	29,514	$	22,162

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the six months ended June 30, 2024 (in thousands):

	Six Months Ended June 30, 2024
	2012 Purchase and Sale Agreement			2020 Purchase and Sale Agreement			Total
Liabilities related to the sales of future royalties, net – beginning balance	$	24,217		$	88,408		$	112,625
Non-cash royalty revenue		(14,104	)		(18,194	)		(32,298	)
Non-cash interest expense		3,488			8,451			11,939
Amortization of transaction costs		—			240			240
Proceeds from the Amendment		—			15,000			15,000
Liabilities related to the sales of future royalties, net – ending balance	$	13,601		$	93,905		$	107,506

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):

	Foreign currency translation			Available-for-sale securities			Accumulated Other Comprehensive Income
Balance at December 31, 2023	$	30		$	50		$	80
Foreign currency translation adjustments		(8	)		—			(8	)
Unrealized gain on available-for-sale securities		—			(475	)		(475	)
Balance at March 31, 2024	$	22		$	(425	)	$	(403	)
Foreign currency translation adjustments		(1	)		—			(1	)
Unrealized gain on available-for-sale securities		—			(90	)		(90	)
Balance at June 30, 2024	$	21		$	(515	)	$	(494	)

	Foreign currency translation			Available-for-sale securities			Accumulated Other Comprehensive Income
Balance at December 31, 2022	$	(5,131	)	$	(1,776	)	$	(6,907	)
Foreign currency translation adjustments		139			—			139
Unrealized gain on available-for-sale securities		—			1,087			1,087
Balance at March 31, 2023	$	(4,992	)	$	(689	)	$	(5,681	)
Foreign currency translation adjustments		13			—			13
Unrealized gain on available-for-sale securities		—			244			244
Reclassification adjustments to income		(1,026	)		—			(1,026	)
Balance at June 30, 2023	$	(6,005	)	$	(445	)	$	(6,450	)